Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas - Test2 - elhamkhani - TriplyDB

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

http://www.wikidata.org/entity/Q24610836

about

Epigenetic therapy in gastrointestinal cancer: the right combination The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma Cholangiocarcinoma IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma Maffucci syndrome and neoplasms: a case report and review of the literature Oncometabolites: tailoring our genes Epigenetic reduction of DNA repair in progression to gastrointestinal cancer Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Therapeutic options for intrahepatic cholangiocarcinoma The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma Metabolic requirements for the maintenance of self-renewing stem cells.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Reporting tumor molecular heterogeneity in histopathological diagnosis.Molecular pathogenesis of cholangiocarcinoma.Diverse modes of genomic alteration in hepatocellular carcinoma Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.Pathogenesis, diagnosis, and management of cholangiocarcinoma Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro Cholangiocarcinoma: molecular pathways and therapeutic opportunities Proximity ligation assay evaluates IDH1R132H presentation in gliomas New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.Molecular diagnosis of intrahepatic cholangiocarcinoma.The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.

P2860

Q26745709-9F55F800-2178-4A71-B5F8-6D7FBF015795 Q26751224-3C30BA6A-A96C-4526-842E-E195B7EF9616 Q26751655-4DC19831-8F73-4200-894D-2E321E813FEB Q26767120-DA62F59F-30DE-48B1-B7A7-A371F69F2123 Q26767392-8946E6AB-F711-4DF4-AE9D-E84A132BBB0C Q26784091-2B14B178-C205-41B4-8F96-E5BEDEAAF9F0 Q26824969-2921310F-4313-49F1-82E4-F68B6C506B9C Q26863394-4755AE93-6B4B-4435-BA21-525DD410B251 Q27001694-2E7945C4-E619-4B1F-9AC9-8FDFD2DE92A8 Q27692015-BE301804-C83E-4BDC-81DA-B5FB056429BF Q27852856-F75F186F-354F-4A4C-8A90-53AAD7A2D02D Q28069937-7A473950-3303-4457-8A58-2C8DDBA6B5A0 Q28085392-28AD8B4A-C260-4F1D-B0B3-872DBD5F30BA Q28262162-DCCEF919-02FB-43C8-8BF1-268AD62157B3 Q30405398-61561F3C-FF79-43FC-AC24-F6C5E54C983D Q32173000-56686859-E016-4FF7-BBA4-BDA10CE3E5DD Q33556447-A418464C-321A-45BA-A280-B5EF012E1A3B Q33581027-794C5B1A-CE90-4A9A-A4B7-7E79BF16F0BB Q33621529-E7EED98A-222C-44B5-B24C-084EE21FBBA7 Q33656860-5FFC2A5C-14B3-4403-A190-206717E30BE3 Q33698756-18E175F6-1C85-43C3-908A-D8D22B25C3FE Q33763540-5400C6D3-A897-4E9F-9F66-78790F438253 Q33893346-2945D634-391C-4FB2-B12A-3820ECF002C0 Q33936179-B07D3967-E75A-4339-9A6F-AD20D036DDCB Q34050798-D9064B23-BE6D-4BEA-9321-51A6D5CF9050 Q34065560-29C6DA2E-E67D-4C50-8D17-1FF82CD5591A Q34306010-502EDBEA-75B2-474A-BFB0-0EA70FCE3D27 Q34327021-6682C0F1-8DD5-4AA4-A1C8-D70AFD19C8A5 Q34374136-D05097A1-4161-4440-9137-B5764FA7B09A Q34499647-AECB556E-9CA4-4A81-8B7F-BE685241F51F Q34656747-8AA0A825-3B34-4636-952D-B4EBB026F920 Q34674381-88B86E4E-9638-48B4-BEBC-41D3EB7E033E Q34959174-C373249A-56AC-4A4A-BC13-829CE335EB41 Q35056736-FD0370D1-7FC2-4DB2-82E8-5F451FF349C1 Q35100996-C18E0BD4-6FB9-4DA0-8F27-6F088B2DC54F Q35592221-85692665-6D9B-40C7-8347-CBA8BCFCF463 Q35756580-0D284716-3029-4A53-BC63-248F57D463B1 Q35842729-BA2CC216-1ABA-41B6-B5EC-152A3F1C4B68 Q35913384-35FC99DB-C29F-498F-B08C-5D4FC7839E7B Q36020846-740F42ED-7E12-4921-A9C8-D7752843C83F

P2860

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

http://www.wikidata.org/entity/Q24610836

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@ast

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@en

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@nl

type

label

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@ast

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@en

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@nl

prefLabel

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@ast

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@en

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@nl

P1433

Q24610836-12634CC2-DCD5-4526-B8A3-1359ED2F6F30

P1476

Q24610836-287AC355-4A46-4D40-B4FB-F82269C12752

P2093

Q24610836-050F3A52-86B9-4D6D-9289-B3C3880AF0B5

Q24610836-06C42FF1-36DD-421D-917C-EEBBCE86E3FB

Q24610836-159142A9-221D-4BAF-A22F-CB87C745CE76

Q24610836-16D45A97-3787-4205-8C69-27B4798B68A8

Q24610836-1AD2C2E4-0F8F-430E-9D98-387B10B7D452

Q24610836-1ED3B4A0-8FA9-462D-9B79-0887143DCEBA

Q24610836-26D4BB72-9125-43EC-A7A7-553140FA7D65

Q24610836-2807E4CB-9C09-4822-B470-CA65156004A7

Q24610836-39EC1A24-05D0-4C41-AEE3-EA814CC0215D

Q24610836-3A2667D2-0620-4BB2-8303-8521AF19A353

P2860

Q24610836-02ABE2CA-2E26-4DD9-B3DC-056970A847DA

Q24610836-0C5D3FA6-EC77-4C81-86D5-DDA990D9B1EC

Q24610836-184BC9D2-3687-44C0-8451-581018F24449

Q24610836-1C26DEDD-565D-4DD4-B474-B41D6C4B3054

Q24610836-1F606CB7-1EB7-491F-AC39-1F9B8AC557BB

Q24610836-251B7D9B-1428-456B-B4BF-FA9A677A07B7

Q24610836-25CB9BD5-3985-4264-B4D0-49B434D3017E

Q24610836-303A8A66-E04A-4216-B00D-62414E3471CC

Q24610836-3D31F9C9-61F5-49E1-9CFC-714AEC157A46

Q24610836-3EE315B8-5AFF-49C9-A701-8179DB99B8B0

P2888

Q24610836-E6B9494D-7AC5-42A6-8707-4CDE6C62EA3D

P304

Q24610836-FF8D54D7-698D-4398-B5FF-CC61F30E9534

P31

Q24610836-FF813271-3F11-495B-ADE1-6A0588729CC3

P3181

Q24610836-5B6148FF-F95E-4FB3-B0F3-B85102DE4F35

P356

Q24610836-5310A740-10BC-45DB-BBB5-512BDFA08671

P407

Q24610836-010959EF-83CB-4559-AD79-BDCBEBD46D3C

P433

Q24610836-CAF6C043-F609-415E-8A9F-50B42D2C91FB

P478

Q24610836-E125545D-C48A-4BDF-8310-A9F4CC3D3FC3

P50

Q24610836-D6FDF9D9-AA3E-4A4F-8ECB-D98BA2DB7E43

P577

Q24610836-B3A81BE6-A4BD-49F0-ACD2-CE552C13EF7A

P5875

Q24610836-4F0E0A4A-52BF-43F2-BEC3-7160A472FC6E

P6179

Q24610836-886C1DBD-6224-49EC-BA2F-A357AC7EB445

P698

Q24610836-1CACBC09-AF33-458D-BA74-31F94B28FBCC

P921

Q24610836-86D14603-690F-4FA6-B406-4B3CFEB73B5A

P932

Q24610836-DB61AB39-7E16-4820-A299-9700DC919305

P3181

P356

P1433

P1476

Mutations in isocitrate dehydr ...... ion targets with glioblastomas

@en

P2093

A D Misher

http://www.w3.org/2001/XMLSchema#string

C D Moser

http://www.w3.org/2001/XMLSchema#string

C Zhang

http://www.w3.org/2001/XMLSchema#string

D Y Chiang

http://www.w3.org/2001/XMLSchema#string

D Ye

http://www.w3.org/2001/XMLSchema#string

G L Savich

http://www.w3.org/2001/XMLSchema#string

H V Hunt

http://www.w3.org/2001/XMLSchema#string

J B Andersen

http://www.w3.org/2001/XMLSchema#string

J M Hoskins

http://www.w3.org/2001/XMLSchema#string

J T Auman

http://www.w3.org/2001/XMLSchema#string

P2860

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

Initial genome sequencing and analysis of multiple myeloma

Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

An integrated genomic analysis of human glioblastoma multiforme

P2888

P304

3091-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1172166

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2012.315

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229552742

http://www.w3.org/2001/XMLSchema#string

P6179

1046269452

http://www.w3.org/2001/XMLSchema#string

P698

22824796

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

3500578

http://www.w3.org/2001/XMLSchema#string